MBRX Moleculin Biotech, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
13:53
Jan 05
Jan 05
Long MBRX for readout catalyst
Author argues MBRX is a long setup ahead of Annamycin data readouts, citing insider buying, abnormal volume, spiking call volume, and a low $7.5M market cap as signs of pending upside. The catalyst is the imminent readout, which he expects to send the low-float stock higher. Analysts' price targets imply roughly 170% upside, and the author says risk/reward is asymmetric. He states he is long and holding for the readout.
HIGH
About MBRX Investor Commentary
Across the available history and selected sources, Buzzberg tracks MBRX (Moleculin Biotech, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/ZealousidealGoose193.